Standard Care: Managing Kidneys and Blood Sugar
At a Glance
FRTS4 care replaces substances the kidneys lose, protects bone health, and monitors for calcium buildup and chronic kidney disease. If HNF4A-MODY develops, sulfonylureas may control blood sugar, but kidney function guides dosing and some people later need insulin.
Managing Fanconi Renotubular Syndrome 4 (FRTS4) requires a “two-front” approach that addresses both the kidneys and the pancreas. Because the condition is so rare, there is no single “standard dose” for everyone. Instead, doctors use a strategy of frequent monitoring and dose adjustment to meet your body’s specific needs [1]. Never adjust fluid intake or supplement doses on your own without consulting your care team, as doing so can be unsafe depending on your kidney function and potassium levels.
Managing Kidney and Bone Health
The primary goal of kidney treatment is to replace what the proximal tubules are losing and to protect the bones from softening (rickets).
- Correcting Acidosis: To prevent the blood from becoming too acidic (metabolic acidosis), patients take “alkali” supplements like sodium bicarbonate or potassium citrate. These act as a chemical buffer. Because the “leakiness” in FRTS4 can be high, your nephrology team will titrate (adjust) the dose based on blood bicarbonate, potassium, eGFR, blood pressure, and volume status [2][1]. Note that sodium bicarbonate adds sodium load, and potassium citrate can be hazardous if potassium levels are high or kidney function is reduced.
- Treating Phosphate Wasting: Because the kidneys leak phosphate, levels in the blood can drop, leading to rickets [3]. Treatment typically involves:
- Preventing Complications: While these supplements are necessary, they can sometimes cause calcium to build up in the kidneys (nephrocalcinosis). Your care team will use regular urine tests and kidney ultrasounds to find the “sweet spot” where bones are healthy but the kidneys are protected [3][5].
Managing Diabetes (HNF4A-MODY)
When the condition transitions into the diabetic phase, the treatment is often different from common Type 1 or Type 2 diabetes.
- Sulfonylureas (First-Line): Many patients with HNF4A-MODY respond very well to oral medications called sulfonylureas [6][7]. These pills help the pancreas release its stored insulin. They are often highly effective and can sometimes replace insulin injections entirely for many years [8][9].
- CKD and Hypoglycemia Risks: Sulfonylurea choice and dosing must be individualized to your eGFR (kidney function). Medications like glyburide (glibenclamide) are generally avoided when kidney function is reduced because they carry a high risk of prolonged, severe low blood sugar (hypoglycemia). Your doctor must carefully choose the specific drug to minimize this risk [10][11].
- Transition to Insulin: Over time, the pancreas may gradually lose its ability to make enough insulin. A portion of patients may eventually need to add insulin injections to their regimen to maintain healthy blood sugar levels [12][13].
Building Your Care Team
Because FRTS4 affects multiple systems, your “medical home” should coordinate between several specialists:
- Nephrologist: Manages the Fanconi syndrome, electrolyte supplements, and monitors for chronic kidney disease (CKD) [14].
- Endocrinologist: Manages the transition from neonatal low blood sugar to HNF4A-MODY [15].
- Medical Geneticist: Assists with variant interpretation and testing for other family members [16].
Some case reports have noted hearing loss or eye/liver abnormalities with certain HNF4A variants [17][18]. While routine syndrome-specific screening for these isn’t universally established, your doctors will investigate these areas if symptoms arise or as part of standard diabetes/CKD care. Because FRTS4 is a progressive condition—with a risk of reaching CKD Stage 3 by adulthood—consistent, long-term follow-up with these specialists is the most effective way to protect your overall health [3].
Common questions in this guide
What medicines are used to treat the kidney problems in FRTS4?
How can FRTS4 treatment protect bones without harming the kidneys?
Is a sulfonylurea safe if I have HNF4A-MODY and reduced kidney function?
Will HNF4A-MODY eventually require insulin?
How often should kidney ultrasounds be done during FRTS4 treatment?
Which specialists should be involved in FRTS4 care?
Get notified when new evidence is published on Fanconi renotubular syndrome 4 with maturity-onset diabetes of the young.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (18)
- 1
Renal Tubular Acidosis.
Bagga A, Sinha A
Indian journal of pediatrics 2020; (87(9)):733-744 doi:10.1007/s12098-020-03318-8.
PMID: 32591997 - 2
Descriptive cohort study of transient isolated tubular acidosis in early childhood: experience from a rare kidney disease expert center.
Charfi H, Bertholet-Thomas A, Bacchetta J, et al.
European journal of pediatrics 2025; (184(10)):613 doi:10.1007/s00431-025-06394-0.
PMID: 40935900 - 3
Phenotypic Spectrum of HNF4α-Associated Fanconi Renotubular Syndrome.
Emma F, Böckenhauer D, Mallett AJ, et al.
Kidney international reports 2026; (11(8)):106616 doi:10.1016/j.ekir.2026.106616.
PMID: 42440446 - 4
Case report: Reversible Fanconi syndrome due to vitamin D deficiency in a patient with epilepsy harbouring a pathogenic variant in the SLC34A1 gene.
Improda N, Rosanio FM, Annicchiarico Petruzzelli L, et al.
Frontiers in endocrinology 2025; (16()):1553032 doi:10.3389/fendo.2025.1553032.
PMID: 40225330 - 5
Rickets guidance: part II-management.
Haffner D, Leifheit-Nestler M, Grund A, Schnabel D
Pediatric nephrology (Berlin, Germany) 2022; (37(10)):2289-2302 doi:10.1007/s00467-022-05505-5.
PMID: 35352187 - 6
Treatment Options for Patients with Maturity-Onset Diabetes of the Young (MODY): A Systematic Review of Literature: 2026 Update.
Zagaroli L, Di Berardino A, Petragnano F, et al.
Diabetes therapy : research, treatment and education of diabetes and related disorders 2026; (17(7)):959-983 doi:10.1007/s13300-026-01884-2.
PMID: 42295651 - 7
Case Report: Beyond type 1 diabetes: a case of delayed MODY1 diagnosis and successful transition to sulfonylurea therapy.
Gulisano C, Aloi C, Salina A, et al.
Frontiers in medicine 2025; (12()):1590935 doi:10.3389/fmed.2025.1590935.
PMID: 40486195 - 8
MODY in Ukraine: genes, clinical phenotypes and treatment.
Globa E, Zelinska N, Elblova L, et al.
Journal of pediatric endocrinology & metabolism : JPEM 2017; (30(10)):1095-1103.
PMID: 28862987 - 9
Clinical characteristics, treatment, and treatment switch after molecular-genetic classification in individuals with maturity-onset diabetes of the young: Insights from the multicenter real-world DPV registry.
Lanzinger S, Laubner K, Warncke K, et al.
Journal of diabetes 2024; (16(11)):e70028 doi:10.1111/1753-0407.70028.
PMID: 39511990 - 10
Clinical Management of Women with Monogenic Diabetes During Pregnancy.
Dickens LT, Naylor RN
Current diabetes reports 2018; (18(3)):12 doi:10.1007/s11892-018-0982-8.
PMID: 29450745 - 11
A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.
Grennan KN, Singh D, Chindris AM, Wilson JR
AACE endocrinology and diabetes 2026; (13(2)):177-179 doi:10.1016/j.aed.2025.12.002.
PMID: 41938282 - 12
Novel Treatment Options in Patients with Maturity-Onset Diabetes of the Young.
Müssig K
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2025; (133(1)):51-58 doi:10.1055/a-2436-7723.
PMID: 39379059 - 13
Identification and precision therapy for three maturity-onset diabetes of the young (MODY) families caused by mutations in the HNF4A gene.
Zhang J, Jiang Y, Li J, et al.
Frontiers in endocrinology 2023; (14()):1237553 doi:10.3389/fendo.2023.1237553.
PMID: 37711893 - 14
Hepatocyte Nuclear Factor-4 Alfa Mutation Associated with Hyperinsulinaemic Hypoglycaemia and Atypical Renal Fanconi Syndrome: Expanding the Clinical Phenotype.
Improda N, Shah P, Güemes M, et al.
Hormone research in paediatrics 2016; (86(5)):337-341 doi:10.1159/000446396.
PMID: 27245055 - 15
Neonatal Hyperinsulinemia and Maternal Diabetes Associated With a Hepatocyte Nuclear Factor 4 Alpha (HNF4A) Variant.
Takasugi Y, Nakagawa R, Ono H, et al.
Cureus 2026; (18(4)):e107058 doi:10.7759/cureus.107058.
PMID: 42147507 - 16
Novel Fanconi renotubular syndromes provide insights in proximal tubule pathophysiology.
Lemaire M
American journal of physiology. Renal physiology 2021; (320(2)):F145-F160 doi:10.1152/ajprenal.00214.2020.
PMID: 33283647 - 17
HNF4A-related Fanconi syndrome in a Chinese patient: a case report and review of the literature.
Liu J, Shen Q, Li G, Xu H
Journal of medical case reports 2018; (12(1)):203 doi:10.1186/s13256-018-1740-x.
PMID: 30005691 - 18
Heterozygous recurrent HNF4A variant p.Arg85Trp causes Fanconi renotubular syndrome 4 with maturity onset diabetes of the young, an autosomal dominant phenocopy of Fanconi Bickel syndrome with colobomas.
Sheppard SE, Barrett B, Muraresku C, et al.
American journal of medical genetics. Part A 2021; (185(2)):566-570 doi:10.1002/ajmg.a.61978.
PMID: 33251707
This page is for informational purposes only and does not constitute medical advice. Your nephrologist, endocrinologist, and geneticist should individualize supplements, fluids, and diabetes treatment based on kidney function and blood sugar.